Status:
COMPLETED
Nasya in Allergic Rhinitis
Lead Sponsor:
InQpharm Group
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate safety and efficacy of Nasya in reducing symptoms of persistent allergic rhinitis when applied before allergen challenge.
Eligibility Criteria
Inclusion
- History of persistent allergic rhinitis due to house dust mite allergy ≥ 2 years
- Written informed consent
Exclusion
- Clinically significant disease that could interfere with the evaluation of study medication
- Participation in other studies within the last 4 weeks / during the study
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01503957
Start Date
January 1 2012
End Date
September 1 2012
Last Update
October 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Campus Charité Mitte Klinik und Poliklinik für Hals-, Nasen-, Ohren- heilkunde Charité - Universitätsmedizin Berlin, Charitéplatz 1
Berlin, State of Berlin, Germany, 10117